Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves' Orbitopathy: A Nonrandomized, Controlled, Interventional Study
Authors' conclusion
Switch to RTX early in the treatment course did not result in better CAS or QoL, compared to continuous intravenous glucocorticoids.
Study context
- Population
- Patients with Graves' orbitopathy started on IV glucocorticoids
- Participants
- 12 / 13 / 12
- Exposure
- Switch to rituximab in IV glucocorticoid non-responders vs continued IV glucocorticoids
- Non-Responders Rituximab (NR-RTX)n = 12
- Responders-Glucocorticoid (R-GC)n = 13
- NR-RCn = 12reference
- Outcome
- CAS (linear mixed model)
- Follow-up
- 4 weeks
Methodological detailsnonrandomized, retrospective control group, clinical activity score (CAS) recorded at 0, 4, 12, 18 and 68 weeks; Quality of life (QoL) and safety collected in NR-RTX and R-GC
- Nonrandomized
- Retrospective control group
- CAS recorded at 0, 4, 12, 18 and 68 weeks; QoL and safety collected in NR-RTX and R-GC
Main finding
As reported in the abstract
Difference
1.21 points
95% CI −2.40 to −0.02
- R-GC had a lower CAS than NR-RTX
- 1.21-point
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Baseline differencesNR-RTX vs NR-RC · 1-point lower median CAS with NR-RTX | P = 0.03 |
| Baseline differencesNR-RTX vs R-GC · twice as many men with NR-RTX | P = 0.03 |
CAS over time · 0–68 weeks
- CAS for all groups converged over time
QoL
- No treatment or time effects on QoL
Original publication
Rituximab Treatment as Second-Line Therapy in Glucocorticoid Nonresponsive Graves' Orbitopathy: A Nonrandomized, Controlled, Interventional Study. Endocr Pract. Published 12 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →